Negotiations to buy Israeli stem cell therapies developer Gamida cell have been terminated, Gamida's parent company said on Thursday. In March, Elbit Medical Technologies - which owns a 30.8 percent stake - said Gamida had received a buyout offer worth hundreds of millions of dollars from an unnamed global pharmaceutical company. Israeli media had identified the interested buyer as Swiss drugmaker Novartis.